Celldex Therapeutics Stock
Price
Target price
?
?
3.320%
1.07
3.320%
€38.97
08:05 / Frankfurt
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
A very strong showing by Celldex Therapeutics today, with an increase of €1.07 (3.320%) compared to yesterday's price.
Our community is currently high on Celldex Therapeutics with 16 Buy predictions and 3 Sell predictions.
With a target price of 38 € there is a slightly positive potential of 14.01% for Celldex Therapeutics compared to the current price of 33.33 €.
So far the community has only identified positive things for Celldex Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 3.320% | 4.368% | -2.272% | 68.901% | 46.636% | 5.425% | -13.186% |
| Northwest Biotherapeutics Inc. | 0.000% | -12.000% | -26.667% | -43.590% | -35.922% | -72.840% | -86.931% |
| Larimar Therapeutics Inc. | -1.130% | 1.807% | 19.858% | 20.714% | 1.807% | -7.143% | -60.925% |
| Achieve Life Sciences Inc. | 1.830% | 1.869% | -0.909% | 151.152% | 47.297% | 10.772% | -11.382% |
Comments
Celldex Therapeutics (CLDX) had its price target raised by Wells Fargo & Company from $48.00 to $72.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Wells Fargo & Company from $54.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Morgan Stanley from $44.00 to $40.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
News
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of
